Semaglutide vs Liraglutide: Is the Older, Cheaper GLP-1 Worth It?

Before semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) dominated the conversation, liraglutide (Victoza for diabetes, Saxenda for weight loss) was the GLP-1 people actually took — once-daily injections, a decade of real-world use, and now a much lower profile as newer drugs have taken over. It hasn't disappeared, and its trial data against semaglutide is more interesting than "the old one lost."

The direct head-to-head trial

Rather than relying on cross-trial comparisons, a phase 2 dose-ranging trial randomized adults with obesity directly to semaglutide, liraglutide, or placebo, testing multiple semaglutide doses against liraglutide 3.0 mg daily over 52 weeks¹. The results were unambiguous on raw weight loss: at week 52, liraglutide produced 7.8% average weight loss, while semaglutide doses of 0.2 mg or higher all beat it, ranging from 11.2% to 13.8%¹. Every semaglutide dose from 0.1 mg upward outperformed placebo's 2.3% substantially, and the trial reported no new safety concerns for either active drug beyond the expected GI symptoms¹.

The diabetes-population comparison tells the same story

A separate head-to-head trial in type 2 diabetes patients, SUSTAIN 10, compared weekly semaglutide 1.0 mg against daily liraglutide 1.2 mg directly. Semaglutide reduced HbA1c by 1.7% versus 1.0% for liraglutide (a statistically significant 0.69-point gap), and produced more weight loss — 5.8 kg versus 1.9 kg². The trade-off: GI side effects were somewhat more common on semaglutide (43.9% vs 38.3% of patients), and more semaglutide patients discontinued due to adverse events (11.4% vs 6.6%)². Semaglutide won on effectiveness in both trials; liraglutide's side-effect and discontinuation profile was somewhat milder in the diabetes comparison.

Where liraglutide holds a real edge: lean mass preservation

Effectiveness isn't the only axis that matters. A 2025 meta-analysis of body-composition outcomes across the GLP-1 class found that "liraglutide, at 3.0 mg weekly or 1.8 mg daily, was the only GLP-1RA to achieve significant weight reduction without significantly reducing lean mass," while the more effective drugs — tirzepatide and semaglutide — were "among the least effective in preserving lean mass"³ specifically because they produce more total weight loss and lean mass tends to track with total loss. See GLP-1 and muscle loss: what the body-composition data actually shows for the fuller picture. This is a real, evidence-based reason someone might genuinely prefer liraglutide beyond just price — not just a consolation prize for the drug that loses less weight.

The cost picture

Liraglutide has been on the market since 2010 (Victoza) and 2014 (Saxenda for weight management), long enough that generic and compounded versions are more established and typically priced lower than newer semaglutide or tirzepatide options from the same cash-pay programs. If your goal is modest and your budget is the binding constraint, liraglutide's lower effectiveness ceiling may simply be enough — the same "match the drug to the goal, not the drug to the hype" logic we apply to semaglutide vs tirzepatide: the cheaper effective GLP-1. The daily injection schedule, versus once-weekly for semaglutide and tirzepatide, is also a real practical trade-off worth weighing — some people prefer the routine of daily dosing, others find once-weekly meaningfully easier to stick with; see GLP-1 dosing and titration: how the schedule actually works for how each drug's titration schedule actually plays out.

The verdict

If effectiveness per dose is your top priority, the trial data is clear: semaglutide beats liraglutide on weight loss and glycemic control in direct comparison, in both an obesity-focused trial and a diabetes-focused trial. If a lower price, a daily-dosing routine, or the specific lean-mass-preservation data matters more to you, liraglutide isn't an outdated relic — it's a different, evidence-backed trade-off, not just the cheaper option by default.

Comparing the actual numbers

Prices and availability shift by provider, so check current pricing before assuming which drug is actually cheaper for you today. Compare cash-pay and compounded pricing across GLP-1 options on our semaglutide price board, and see how we weigh effectiveness against cost in our Value Score methodology.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.